Introduction {#s1}
============

Metabolic syndrome (MetS), including obesity, hypertension, hyperglycemia, and dyslipidemia, has detrimental effects on the endothelium, contributing to the development of cardiovascular diseases (CVD) ([@B60]; [@B97]). One of the key common central mechanisms linking all of these diseases is underpinned by an exaggerated inflammatory response ([@B48]). In recent years, evidence has accumulated that chemokine receptor 5 (CCR5) and its ligands play a critical role in regulating the inflammatory response. For example, CCR5 aggravates the inflammatory response in mouse adipose tissue by regulating macrophage recruitment and M1/M2 phenotype switching, thus causing insulin resistance and obesity ([@B39]). Inhibition of CCR5 expression reduces the accumulation of pro-atherogenic cytokines and monocytes to the site of arterial injury. However, therapies targeting CCR5 and its ligands have not performed consistently with regard to preventing metabolic syndrome related diseases ([@B37]; [@B78]), indicating that CCR5 and its ligands might play a double-edged role in the progression of these diseases. More importantly, emerging evidence shows that CCR5 is specifically expressed in endothelial cells and endothelial progenitor cells (EPCs). CCR5 facilitates progenitor cell recruitment and promotes vascular endothelial repair in a mouse model ([@B34]; [@B82]; [@B98]). Although inhibiting CCR5 expression reduces the inflammatory response, it also aggravates the endothelial damage, thus significantly limiting the actual effectiveness of therapeutic interventions. Therefore, studying the mechanisms of CCR5 and its ligands that control these processes in the endothelial cells and the inflammatory response will provide further understanding of the pathophysiology of cardiovascular disease and may be used to develop novel pharmacological strategies.

CCR5 and Its Ligands {#s2}
====================

CCR5, a member of the guanine nucleotide binding protein (G protein) coupled receptors (GPCR), has been known as a key player in HIV-1 entry into target cells from its discovery ([@B9]). CCR5 binds and responds to chemokine ligand 3 (CCL3) ([**Table 1**](#T1){ref-type="table"}), chemokine ligand 4 (CCL4), and chemokine ligand 5(CCL5). CCR5 is expressed in macrophages, activated T cells, natural killer cells, endothelial cells, and EPCs. CCR5 participates in the regulation of proinflammatory response by modulating the behavior, survival, and retention of immune cells in tissues ([@B41]). In addition, CCR5 can be expressed in non-immune system cells, notably in astrocytes, microglia, and neurons, which are involved in neuronal survival and differentiation ([@B81]).

###### 

Summary of data of CCR5 and its ligands, primary source, main effects, and main references.

  Gene name   Expressed by/primary source                                                                                                                                   Main effects                                                                                                                                                                                                              References                                                                                                                                                                                            
  ----------- ------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------
  **CCL3**    Monocytes/macrophages, T cells, vascular smooth muscle cells, eosinophils, coronary endothelial cells, and platelets.                                         Mediates the recruitment of macrophages into the injured site by binding with its receptor, CCR5.                                                                                                                         CCL3 induces the infiltration of macrophages into the damaged retina and produces vascular endothelial growth factor (VEGF) by binding to CCR5, and eventually promotes corneal neovascularization.   [@B70]; [@B52]; [@B22]; [@B47].
  **CCL4**    Monocyte, T cells, B lymphocytes, NK cells, dendritic cells, vascular smooth muscle cells, and neutrophils.                                                   Chemoattractants for immature dendritic cells and macrophages/monocytes, attracts macrophages to destroy islet cells.                                                                                                     Increases VEGF-C expression and promotes lymph angiogenesis in oral cancer cells.                                                                                                                     [@B70]; [@B52]; [@B16]; [@B44].
  **CCL5**    T-cells, epithelial cells and activated platelets                                                                                                             Mediates the macrophage recruitment and M1/M2 phenotype switching, recruits leukocytes and certain natural-killer cells, promotes smooth muscle cells phenotypic switching from the contractile to synthetic phenotype.   CCL5 is pro-angiogenic in the ischemic tissues and subcutaneous model, promotes the revascularization and muscle regeneration by binding to its receptor, CCR5.                                       [@B82]; [@B46]; [@B98]; [@B70]; [@B45].
  **CCR5**    Monocytes/macrophages, activated T cells, endothelial cells, endothelial progenitor cells (EPCs), natural killer cells, astrocytes, microglia, and neurons.   Promotes infiltration of monocytes/macrophages to the injured site, aggravates hepatic steatosis and insulin resistance, and increases triglyceride synthesis.                                                            Accelerates the homing of EPCs to damaged endothelial cells, promoting endothelial repair or the formation of neovascularization.                                                                     [@B83]; [@B11]; [@B71]; [@B67]; [@B10]; [@B34]; [@B39]; [@B75]; [@B46]; [@B98]; [@B70]; [@B63]; [@B95].

CCL3, also known as macrophage inflammatory protein-α (MIP-α), is released from activated platelets, mast cells, and neutrophils ([@B91]; [@B57]). Previous studies indicated that CCL3 activates neutrophils *via* the mediation of firm adherence and the (subsequent) transmigration of neutrophils as a result of lipid mediator production. CCL4 is also called macrophage inflammatory protein-β (MIP-β) and was first isolated from culture medium containing lipopolysaccharide-activated macrophages. CCL4 can induce the chemotaxis of different cell types, including natural killer cells, monocytes/macrophages, and coronary endothelial cells ([@B55]). The chemotactic activity of CCL5, initially considered to be a T cell-specific protein that is stored in and released from various cells, including endothelial cells, EPCs, monocytes/macrophages and fibroblasts, recruits activated T cells, NK cells, and basophils to the site of an inflammatory response ([@B5]).

CCR5 and Its Ligands in Relation to Endothelial Function {#s3}
========================================================

Endothelial cells line the interior surface of all blood vessels and are involved not only in delivering blood to all vital organs but also in maintaining the homeostasis of the vasculature. A large body of evidence has shown that diabetes, ischemia, and atherosclerosis ([@B82]; [@B98]; [@B2]) have adverse effects on the endothelium, which contributes to the development of CVD. One of the key common central mechanisms linking all of these diseases is based on exaggerated inflammation. In all cases, the interaction between the endothelium and inflammatory cells plays a key role in the initiation of the pathological condition.

Previous studies have demonstrated that chemokines can directly regulate the migration and recruitment of cells to injury sites *via* inflammation. All CC-chemokines contain nuclear factor-kappa B (NF-κB) binding motifs, and their expression is significantly upregulated under inflammatory conditions ([@B92]; [@B70]). CCL3, CCL4, and CCL5 are upregulated when induced by an inflammatory stimulus ([@B42]; [@B99]; [@B70]). Increased expression of CCL3/CCL4/CCL5 mediates the arrest and transmigration of monocytes/macrophages into the damaged endothelium by binding with its receptor CCR5 ([@B98]; [@B70]), which is involved in the inflammatory response to endothelial injury. Blocking CCR5 alleviated myocardial ischemia--reperfusion injury in rats by regulating the cardiac inflammatory response ([@B75]). CCR5 deficiency could reduce macrophage aggregation into atherosclerotic plaques in a hypercholesterolemic mouse model ([@B67]).

In addition to their roles in mediating inflammation, CCL5 has also been shown to play a role in the process of ischemia-mediated physiological angiogenesis ([@B83]; [@B11]) and endothelial repair (Maarten B. et al., 2007; [@B98]; [@B95]). CCL5/CCR5 is specifically expressed in endothelial cells and EPCs, and endothelial cell specific CCR5 is involved in the regulation of vascular regeneration in ischemic tissues ([@B83]). Administration of CCL5-loaded microparticles could improve the clinical score of mice after limb injury as well as promote the revascularization and the muscle regeneration. [@B95] verified that CCR5 expression was upregulated in vascular endothelial growth factor (VEGF) modified macrophage *in vitro* after treatment with VEGF-modified macrophages therapy accelerated reendothelialization and attenuated neointima formation in the wire-induced carotid artery injury mouse model. CCL5 is pro-angiogenic in a rat model of subcutaneous injury. One *in vitro* study found that the effects of CCL5-mediated angiogenesis are at least partially dependent on VEGF secretion by endothelial cells, as the effects are weaker when endothelial cells are incubated with anti-VEGF receptor antibodies ([@B82]). According to the leucocyte subset chemokine expression, patients with age-related macular degeneration (AMD) of neovascularization have different responses to anti-VEGF receptor antibody treatment, with good responders to the anti-VEGF loading dose having higher CCR1 expression on monocytes and lower CCR5 expression on CD14^+^ T cells, indicating that CCR5 may be an effective way to provide individualized treatment for neovascular AMD ([@B11]).

EPCs, as a kind of precursor cell derived from bone marrow that can differentiate into endothelial cells, play an important role in neovascularization during tissue repair ([@B98]). In a mouse skin injury model, deletion of the CCR5 gene reduced the accumulation of vascular EPCs and the formation of neovascularization, and it eventually delayed the healing of damaged skin. When EPCs carrying the CCR5 gene are transferred into CCR5^-/-^ mice, EPCs accumulated at the site of injury and restored normal neovascularization ([@B34]). CCL5 is involved in the homing of bone marrow-derived EPCs in glomerular endothelial repair. In a mouse model of reversible glomerulonephritis, administration of a CCR5 inhibitor (METRANTES) reduced the participation of EPCs in glomerular vascular repair ([@B71]). In a hypercholesterolemic ApoE^-/-^ mouse model, overexpression of CCR5 contributes to the homing of EPCs to damaged endothelial cells, promoting endothelial repair, improving endothelial dysfunction, and ultimately stabilizing atherosclerotic plaques ([@B98]).

CCR5 and its ligands play an important role in regulating tissue angiogenesis, but the exact mechanism is still unclear. A study ([@B46]) on human chondrosarcoma cells revealed that pretreatment with a phosphatidylinositol 3-kinase (PI3K) inhibitor repressed the VEGF production and angiogenesis induced by CCL5/CCR5, suggesting that the PI3K-dependent pathway plays a crucial role in CCL5/CCR5-mediated angiogenesis.

In addition to CCL5, CCL3 and CCL4 are also involved in the process of revascularization. In alkali-induced corneal neovascularization of mouse models, CCL3 could induce the infiltration of macrophages into the damaged retina and the production VEGF by binding to CCR5, eventually promoting corneal neovascularization ([@B47]). Anti-CCL3 antiserum has been shown to decrease angiogenic activity in a murine wound repair model ([@B22]). CCL4 was proven to increase VEGF-C expression and promote lymphangiogenesis in oral cancer cells ([@B44]).

CCR5 and Its Ligands in Metabolic Syndrome {#s4}
==========================================

Obesity {#s4_1}
-------

Obesity is characterized as low-grade systemic or chronic inflammation that is associated with an increased incidence of metabolic syndrome, cardiovascular disease, and tumor ([@B21]; [@B60]). Excessive fat tissue expansion triggers the secretion of cytokines and chemokines ([@B15]), which in turn attract various leukocytes, leading to fatty tissue inflammation.

The exact role of CCR5 and its ligands in the pathogenesis of obesity is still obscure, but there are several studies that have continuously reported this finding ([@B97]). [@B25] noted that phosphatidyl-ethanol-amine-N-methyl transferase-deficient mice were resistant to high fat diet-induced obesity. This may result from decreased expression of CCL5. Similarly, [@B65] found that weight gain in patients on antipsychotics is associated with the extent of CCL5 expression. CCL5, as a neuroendocrine element, modulates food intake and body temperature of C57BL/6 mice through unidentified receptors in the hypothalamus ([@B17]), thus affecting the body weight. In a high-fat diet-induced obese mouse model ([@B39]), CCR5 plays a critical role in adipose tissue macrophage recruitment and polarization. Deletion of CCR5 reduces the transition of macrophages from the pro-inflammatory M1 phenotype to the anti-inflammatory M2 phenotype and ameliorated obesity-induced insulin resistance. This observation is consistent with previous studies that have indicated that CCR5 could directly induce the transition of the M1/M2 phenotype by modulating the alteration of Ly6C ^high^ and Ly6C ^low^ monocyte subsets ([@B80]; [@B31]); further studies are required to clarify the details of this mechanism.

Hyperglycemia {#s4_2}
-------------

CCR5 and its ligands have been shown to be associated with the pathogenesis of both type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM). As we know, the main pathological mechanism of T1DM is the pancreatic islet β-cell death ([@B6]). CCL4 is upregulated in the islet autoantibody-positive T1DM patients and relatives at high risk of developing T1DM, and increased expression of CCL4 aggravates β-cell death and early islet graft loss by stimulating the trafficking of macrophages into injured pancreatic islets ([@B30]). Moreover, the extracellular regulated protein kinases and NF-kB pathway may be involved in the process of CCL4 production by stimulating CD40-CD40L interaction in human pancreatic islets ([@B7]).

In patients with diabetes, CCL5 and CCR5 are upregulated in the peripheral blood ([@B79]; [@B33]). Exogenous insulin supplementation may reduce concentrations of CCL5 in patients with newly diagnosed type 2 diabetes compared with the control subjects ([@B12]). Epidemiological studies have indicated that CCR5 promoter function mutation (CCR5 59029 G to A alteration) could be a susceptibility factor for type 2 diabetes and the CCR5 59029 A positive genotype increased the risk for type 2 diabetes ([@B40]). The exact mechanism of CCR5 gene mutation and the pathogenesis of type 2 diabetes are still unclear. Since the metabolic hallmark of type 2 diabetes is insulin resistance, previous studies have shown that CCR5 gene knockout in mice could prevent insulin resistance and diabetes induced by a high-fat feeding. The beneficial effects of CCR5 deficiency were correlated with reduced recruitment and the M2-dominant shift of macrophages in adipose tissues ([@B39]). However, this finding is contrary to Chou et al' s studies, which suggested that the CCR5 gene knockout in mice impairs the regulation of energy metabolism in the hypothalamus ([@B17]). Both *in vitro* tissue culture and *ex vivo* stimulation studies indicated that the activation of PI3K-Akt pathways and insulin signaling were impaired in the hypothalamus of CCR5 knockout mice. METRANTES, a CCR5 antagonist, abolished the dephosphorylation of insulin receptor substrates-1 (IRS-1)^S302^ and insulin signal activation. In addition, intracerebroventricular delivery of the CCR5 antagonist interrupted hypothalamic insulin signaling and led to glucose intolerance. In summary, CCR5 may be involved in the pathogenesis of type 2 diabetes through mediating insulin resistance and hypothalamic insulin signaling regulation. However, there are still many unanswered questions about the exact effect of CCR5 in the pathogenesis of type 2 diabetes. Additional research is needed in the future to confirm this conclusion.

Microvascular complications are the leading cause of death in diabetic patients. The recruitment of leukocytes to kidney tissue during T2DM is an early event in the pathogenesis of diabetic kidney disease (DKD). CCR5 mRNA was faintly detected in the normal tubulointerstitial compartment tissue ([@B53]). After the high glucose treatment, CCR5 expression was upregulated in the tubulointerstitial compartment during the process of diabetes. Since CCL5/CCR5 participates in the formation of inflammatory infiltrates during glomerulonephritis, inhibition of CCR5 exerts renal protection during early glomerulonephritis through its anti-inflammatory properties ([@B86]). The correlation between the CCR5 gene and the risk of DKD is conflicting and inconclusive. An oral CCR2/CCR5 antagonist (PF-04634817) slightly reduced albuminuria in adults with DKD ([@B24]). However, in ob/ob mice, treatment with a dual CCR2/CCR5 antagonist (MK-0812) showed no protective effect on DKD ([@B61]). Although adipose tissue inflammation was decreased in this mouse model, the improvement was insufficient to overcome the metabolic imbalances of type 2 diabetes. The mutations in the CCR5 gene promoter region (CCR5 59029 G to A alteration) and deletion of 32 nucleotides (CCR5-Δ32) lead to genetic inactivation of CCR5 ([@B59]). Previous studies have found that CCR5-59029 G/A was an independent risk factor for DKD ([@B94]). The CCR5 59029A-positive genotype was correlated with an increased risk for albuminuria ([@B100]). [@B56] showed that the CCR5-Δ32 mutation increased the risk of kidney disease in men with type 1 diabetes; however, this outcome is contrary to that of [@B68] who found that CCR5-Δ32 was not related to nephropathic type 2 diabetes patients. [@B77] even indicated that 32 allele-bearing individuals exhibit more beneficial values of kidney function parameters. Specifically, the wt/∆32 and ∆32/∆32 carriers exhibited a higher number of CD34^+^VEGFR^2+^ and CD34^+^VEGFR^2+^c-Kit^+^ cells than that in the wild type counterparts.

In addition, CCR5-Δ32 gene mutation was associated with retinopathy in patients with type 1 diabetes. Previous studies indicated that tumor necrosis factor (TNF)-α, vascular cell adhesion molecule (VCAM)-1, and intercellular cell adhesion molecule (ICAM)-1 were upregulated in diabetic patients with *CCR5*-Δ32 carriers ([@B36]; [@B78]). TNF-α plays a major role in the degeneration of retinal capillaries. Since ICAM-1 is the primary adhesion molecule involved in the pathogenesis of diabetic retinopathy (DR), the elevated level of ICAM-1 may facilitate the recruitment of leukocytes into the damaged retina ([@B51]). Thus, the mutation of CCR5 gene (CCR5-Δ32) in the retina may lead to upregulating expression of other cytokines that exacerbate retinal damage.

Dyslipidemia {#s4_3}
------------

Diabetes is often accompanied by dyslipidemia as a result of insulin resistance. Dyslipidemia has been demonstrated to be detrimental to diabetes microvascular and macrovascular complications ([@B19]; [@B50]).

Clinical research has shown that the expression levels of CCL5 and CCR5 were increased in the subcutaneous adipose tissue of obese individuals in comparison with those in the lean population, which could be reduced back to the normal levels through physical exercise ([@B8]). One study ([@B38]) reported that ultraviolet irradiation of human sun-protected subcutaneous fat *in vitro* could induce CXCL5 and CCL5 production; CCL5 treatment dose-dependently reduced triglyceride (TG) content and downregulated the expressions of acetyl CoA carboxylase (ACC), fatty acid synthase (FAS), stearoyl CoA desaturase (SCD), and sterol regulatory element-binding protein-1(SREBP-1) in human adipocytes. The changes could be reversed when the CCL5 receptor, the CCR5 gene, is deleted, suggesting that CCL5 impairs the synthesis of TG by reducing the expression of SREBP-1 and lipogenic enzymes through binding to its receptor, CCR5. In a nonalcoholic fatty liver disease mouse model, treatment with a CCR5 antagonist, maraviroc, could ameliorate hepatic steatosis *via* downregulation of dietary lipid absorption or *de novo* lipogenesis ([@B63]). This also accords with [@B39] earlier observations, which showed that the deletion of the CCR5 gene reduced the content of TG and the lipogenic genes expression in mice. Similarly, [@B10] even found that the administration of CCR5 antagonist markedly ameliorated hepatic fibrosis and accelerated fibrosis regression in mouse models of liver fibrosis. Epidemiological research ([@B32]) has also shown that there was a significant positive correlation between the CCR5-Δ32 mutation and elevated serum high-density lipoprotein cholesterol (HDL) and reduced serum TG, both of which are beneficial from a cardiovascular perspective.

In addition to endothelial cells, dyslipidemia could drive the phenotypic modulation of smooth muscle cells (SMCs) and cause SMCs phenotypic alteration from the physiologically contractile to the pathophysiologically synthetic phenotype. CCR5 and CCL5 play crucial roles in the phenotypic modulation of SMCs. In HFD fed mouse model, the CCR5 and CCL5 gene knockouts showed significantly decreased levels of serum lipids and increased expressions of the SMCs contractile phenotype in the thoracoabdominal aorta as compared with the levels observed in wild-type mice. *In vitro*, CCL5 treated human aorta derived SMCs could induce cell proliferation and promote the phenotypic switching from the contractile to the synthetic phenotype ([@B45]).

Hypertension {#s4_4}
------------

Hypertension is an important risk factor for the development of cardiovascular diseases ([@B64]). Previous studies have shown that angiotensin II (Ang II) promotes the infiltration of T cells and monocytes into perivascular adipose tissues (pVAT) ([@B54]). Subsequent studies have demonstrated that the activation and recruitment of T cells and monocytes into pVAT is very important in the pathogenesis of renin-angiotensin system (RAS)-dependent hypertension ([@B28]).

CCL5 is produced by several tissues that contribute to the regulation of the vasoconstriction and diastolic function, such as the vascular endothelium, vascular smooth muscle ([@B35]), glomeruli ([@B93]), renal tubules ([@B90]), and the central nervous system ([@B27]). CCL5 expression is upregulated in the aorta and pVAT during RAS-dependent hypertension. Previous studies have shown that there is a significant positive correlation between CCL5 expression and blood pressure in the Ang II-induced hypertension mouse model ([@B54]). CCL5 could enhance the genesis of perivascular inflammation, thus affecting the development of hypertensive vascular dysfunction. The deletion of CCL5 reduces the infiltration of leukocytes and T lymphocytes into pVAT and importantly, this is independent of blood pressure changes.

Furthermore, the effects of CCL5 signaling on hypertensive organ damage appear to be tissue-and context-dependent. For example, CCL5 and CCR5 are possibly involved in the pathogenesis of pulmonary arterial hypertension (PAH). CCL5 can be released from endothelial cells and perivascular fibroblasts. Anti-endothelial cell antibody (AECA)-positive systemic sclerosis patients are associated with an increased risk of PAH, which may result from the increased CCL5 expression induced in endothelial cells by the stimulation with AECA. CCR5 is expressed in the macrophages, pulmonary artery endothelial cells, and pulmonary artery smooth muscle cells. Inhibition of CCR5 expression in mice model decreased perivascular macrophages recruitment and the proliferation of pulmonary-artery smooth muscle cell during hypoxia exposure ([@B49]). However, this finding is contrary to previous studies which have suggested that CCL5 plays an important protective role in hypertension-induced renal injury. In the angiotensin II-induced hypertension mice model, CCL5 gene deficiency exhibited markedly aggravation of kidney damage, macrophage infiltration, and proinflammatory cytokine expression, which led to the aggravation of urinary albumin excretion ([@B72]). This may be explained by the blockade of one chemokine leading to the upregulated expressions of other cytokines that exacerbate RAS-dependent hypertension, as CCL2 blockade abrogates the enhanced renal macrophage infiltration and interstitial fibrosis in CCL5-deficient mice ([@B54]; [@B73]).

Atherosclerosis {#s4_5}
---------------

Atherosclerosis is characterized by the accumulation of lipids, immune cells, and cell debris in the vessel wall, which form atherosclerotic lesions that can grow over time and eventually occlude the blood vessels, leading to ischemia and angina ([@B29]; [@B66]). As a chronic inflammatory disease, atherosclerosis is associated with many chemokines and chemokine receptors ([@B98]; [@B3]; [@B87]).

In recent years, much attention has been focused on the role of CCR5 and its ligands, which is crucial in the context of atherosclerosis initiation and progression ([@B62]; [@B1]; [@B99]). CCR5 is expressed in the endothelial cells, monocytes/macrophages, and leukocytes ([@B80]). CCL5 may be released from activated platelets and T cells. During the progression of atherosclerotic disease, CCR5 and CCL5 proteins are faintly detected when there are no visible atherosclerotic plaques and are highly expressed in the stable plaques and advanced unstable plaques ([@B98]). Activated platelets release CCL5 ([@B26]), transferring CCL5 to the surface of injured endothelial cells and leading to increased monocyte/macrophage and leukocyte adhesion to the atherosclerotic vascular wall by binding with its receptor, CCR5 ([@B80]; [@B98]), both of which are adverse effects from a cardiovascular perspective. The deletion of the CCR5 gene in apolipoprotein E-deficient (ApoE^-/-^) mice has a protective effect on diet-induced atherosclerosis and reduces the infiltration of mononuclear and Th1 type immune response. CCR5 is also associated with a more stable plaque phenotype ([@B13]). Administration of the CC chemokine antagonist METRANTES ([@B88]) or treatment with \[^44^AANA^47^\]-RANTES ([@B14]) inhibits the progression of atherosclerosis in a hyperlipidemic mouse model. This inhibition of lesions is associated with reduced infiltration of leukocytes into plaques and increased content of smooth muscle cells and collagen content, indicating a more stable plaque phenotype. Systemic CCL5 deficiency in ApoE^-/-^ mice was found to cause reduced neointima formation after carotid artery injury ([@B20]). The atheroprotective effect of CCL5 deficiency might be mediated by the upregulation of kruppel-like factor 4 expression in smooth muscle cells. For HIV-infected patients, treatment with a CCR5 antagonist (Maraviroc) could significantly improve endothelial dysfunction, arterial stiffness, and early carotid atherosclerosis ([@B23]). Matrix metalloproteinases (MMP) are involved in the vascular remodeling and immunomodulation during the process of atherosclerosis ([@B18]). Studies have demonstrated that mice deficient for MT4-MMP have higher numbers of patrolling monocytes/macrophages adhered to inflamed endothelial cells, leading to larger lipid deposits in atherosclerotic plaques. Interestingly, these effects could be reversed by CCR5 inhibition ([@B18]). However, epidemiological studies have shown that the association between CCR5 gene mutation and the risk of atherosclerosis-related diseases is conflicting and inconclusive. Previous studies have found that CCR5-Δ32 allele bearing individuals exhibit more beneficial values of cardiovascular function parameters ([@B62]; [@B1]; [@B32]). There was a significant positive correlation between CCR5-Δ32 allele bearing individuals and reduced susceptibility to CVD ([@B1]) or development of CVD in a North Indian population ([@B62]). This may be due to CCR5 deficiency affecting lipid metabolism ([@B32]). CCR5-Δ32 was significantly associated with higher levels of HDL-C and lower levels of TG, both of which are beneficial from a cardiovascular perspective. However, this outcome is contrary to those of [@B74] and [@B4] who found that there was no significant difference between the CCR5-Δ32 and the risk of CVD. [@B99] even indicated that the CCR5-Δ32 increased the risk of atherosclerotic disease in Asian population ([@B99]). Moreover, previous studies have reported that a CCR5 gene promoter region mutation (CCR5-59029 G/A) was an independent risk factor for CVD ([@B76]; [@B89]). The CCR5 59029A-positive genotype was correlated with an increased risk of acute coronary syndrome ([@B85]). Considering that the role of CCR5 gene mutation in the risk of CVD is controversial, further studies with more focus on the association is therefore suggested.

In addition to CCL5, CCL3 and CCL4 have also been reported to participate in the process of atherosclerosis. CCL3 was highly expressed in atherosclerotic plaques, and the treatment with atorvastatin alleviated atherosclerotic lesions through inhibition of the 5-Lipoxygenase pathway and downregulation of CCL3 expressions in an atherosclerotic mouse model ([@B96]). CCL4 was also upregulated in vulnerable atherosclerosis plaques and was expressed by T cells in advanced atherosclerotic lesions in stroke patients ([@B58]). Studies has been conducted in a cohort of hypertensive patients for an average follow-up period of 37.2 ± 19.9 months; the result found that elevated serum CCL4 levels is an independent predictor of stroke and cardiovascular events ([@B84]).

Discussion {#s5}
==========

It is generally assumed that CCR5 and its ligands play a critical role in promoting inflammation by recruiting immune cells, such as monocytes and T cells. They may contribute to insulin resistance by M1/M2 phenotype switching of macrophages that infiltrate adipose tissues ([@B39]). On the one hand, an impaired insulin signal *via* PI3K-Akt directly reduces endothelial NO synthase (eNOS) activation ([@B69]), leading to endothelial dysfunction. On the other hand, long-term exposure of endothelial cells to high levels of glucose induces cellular dysfunction ([@B15]) and production of CCR5 and its ligands ([@B43]). Adipokines, primarily adiponectin and TNF-α, secreted by fat tissue, also contribute to endothelial damage ([@B69]), which is regarded as the initiation of cardiovascular diseases. CCR5 seems to be associated with endothelial dysfunction *via* proinflammatory activity ([**Figure 1A**](#f1){ref-type="fig"}) ([@B97]).

![Chemokine receptor 5, a double-edged sword in the inflammatory response and endothelial repair during the process of metabolic syndrome and cardiovascular disease. **(A)** The proinflammatory role of CCR5 and its ligands in metabolic syndrome and cardiovascular disease. As shown in section **(A)**, obesity is characterized as low-grade systemic or chronic inflammation that is associated with increased incidence of metabolic syndrome and cardiovascular disease. CCR5 and its ligands are associated with systemic inflammation. (1) CCR5 and its ligands promote the transition of macrophages from the pro-inflammatory M1 phenotype to the anti-inflammatory M2 phenotype and aggravate obesity-induced insulin resistance; (2) CCR5 and its ligands promote infiltration of leukocytes into plaques and endothelial permeability, decrease the content of smooth muscle cells and collagen content, indicating a more vulnerable plaque phenotype; (3) CCL5 increases the synthesis of triglyceride and hepatic steatosis through binding to its receptor, CCR5; (4) CCL5 could induce smooth muscle cell proliferation and promote the phenotypic switching from the contractile to the synthetic phenotype; **(B)** CCR5 and its ligands are involved in the endothelial repair during the process of endothelial damage. As shown in section **(B)**, CCL3, CCL4, and CCL5 contain NF-κB binding motifs and are upregulated when induced by an inflammatory stimulus. Increased expression of CCL3/CCL4/CCL5 mediates the mobilization and recruitment of bone marrow derived-endothelial progenitor cells into the damaged endothelium by binding with its receptor, CCR5. In addition, CCL3, CCL4, and CCL5 could directly stimulate injured cells, increase nitric oxide production, and promote endothelial cell migration and proliferation to the injured sites.](fphar-11-00146-g001){#f1}

However, therapies targeting CCR5 and its ligands are not always satisfactory. Populations with CCR5-Δ32 are not consistently protected from diabetes and its complications. Deletion of CCR5 or treatment with a CCR5 antagonist in mouse model did not always reverse the inflammatory status in metabolic syndrome. One possible explanation may be that blockade of one chemokine leads to the upregulated expressions of other cytokines that exacerbate cellular dysfunction and inflammation. Another explanation may point to the potential therapeutic effect role of CCR5 in endothelial repair. The macrophages recruited by CCR5 may release various pro-angiogenic factors, including VEGF, basic fibroblast growth factor (bFGF), and platelet derived growth factor (PDGF) ([**Figure 1B**](#f1){ref-type="fig"}) ([@B70]). In addition, CCR5 facilitates the recruitment of EPCs into injured vessels and enhances endothelial regeneration, which may also explain the genetic inactivation of CCR5 as an independent risk factor for DR and DKD ([@B78]).

CCR5 is a double-edged sword for metabolism-related cardiovascular diseases, which may result from the patients with varying degrees of damage at different growth stages. In addition, the specificity of populations and organs should also be taken into consideration. Further studies are required to clarify the details of the mechanism.
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